1-12 of 12
Todd M. Bauer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Hans Gelderblom, Albiruni A. Razak, Matthew H. Taylor, Todd M. Bauer, Breelyn Wilky, Javier Martin-Broto, Alejandro F. Gonzalez, Piotr Rutkowski, Bartlomiej Szostakowski, Thierry Alcindor, Ramy Saleh, Sofia Genta, Silvia Stacchiotti, Michiel van de Sande, Andrew J. Wagner, Nicholas Bernthal, Lara E. Davis, Jacqueline Vuky, Christopher Tait, Bahar Matin, Supraja Narasimhan, Maitreyi G. Sharma, Rodrigo Ruiz-Soto, Matthew L. Sherman, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3996–4004.
https://doi.org/10.1158/1078-0432.CCR-24-0103
Published: 13 September 2024
View article titled, CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Open the PDF for CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib in another window
Includes: Supplementary data
Journal Articles

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4871–4884.
https://doi.org/10.1158/1078-0432.CCR-22-0612
Published: 14 November 2022
View article titled, Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Open the PDF for Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Jonathan W. Goldman, Sarina A. Piha-Paul, Brendan Curti, Katrina S. Pedersen, Todd M. Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A. Hammond, Katie Streicher, Danielle M. Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, John Powderly
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3709–3719.
https://doi.org/10.1158/1078-0432.CCR-21-3016
Published: 01 September 2022
View article titled, Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Open the PDF for Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Funda Meric-Bernstam, Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan, Angela DeMichele, Naomi B. Haas, Manish R. Patel, James J. Harding, Martin H. Voss, Taofeek K. Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C. Bendell, Yonchu Jenkins, Sam H. Whiting, Keith Orford, Mark K. Bennett, Todd M. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1540–1548.
https://doi.org/10.1158/1078-0432.CCR-21-2972
Published: 14 April 2022
View article titled, Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Open the PDF for Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 429.
https://doi.org/10.1158/1078-0432.CCR-21-4241
Published: 15 January 2022
View article titled, Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Journal Articles

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip B. Komarnitsky, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5781–5792.
https://doi.org/10.1158/1078-0432.CCR-21-0765
Published: 01 November 2021
View article titled, Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
Open the PDF for Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5236–5247.
https://doi.org/10.1158/1078-0432.CCR-21-0715
Published: 01 October 2021
View article titled, Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em>
Open the PDF for Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em> in another window
Includes: Supplementary data
Journal Articles

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O'Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda Merchant, Gayle Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, Kris Sachsenmeier
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2176–2187.
https://doi.org/10.1158/1078-0432.CCR-19-2183
Published: 01 May 2020
View article titled, Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Open the PDF for Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

James J. Harding, Andrew X. Zhu, Todd M. Bauer, Toni K. Choueiri, Alexander Drilon, Martin H. Voss, Charles S. Fuchs, Ghassan K. Abou-Alfa, Sameera R. Wijayawardana, Xuejing Aimee Wang, Brian A. Moser, Arantxa Uruñuela, Volker Wacheck, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5202–5211.
https://doi.org/10.1158/1078-0432.CCR-18-4010
Published: 03 September 2019
View article titled, A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Open the PDF for A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine

Ursula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek, Jan Pinkas, Stella K. Kim
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1727–1736.
https://doi.org/10.1158/1078-0432.CCR-18-2474
Published: 15 March 2019
View article titled, Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine
Open the PDF for Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine in another window
Journal Articles

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martinez, Enaksha Wickremsinhe, Aaron Fink, Volker Wacheck, Kathleen N. Moore
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3253–3262.
https://doi.org/10.1158/1078-0432.CCR-17-3421
Published: 15 July 2018
View article titled, A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Open the PDF for A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M. Bauer, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin V. Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine R. Murray, Jennifer L. Schutzman, Jennifer O. Lauchle, Jean-Charles Soria, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2423–2432.
https://doi.org/10.1158/1078-0432.CCR-16-1782
Published: 14 May 2017
View article titled, Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Open the PDF for Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data